TSX:HBP - Toronto Stock Exchange - CA4229102088 - Common Stock - Currency: CAD
TSX:HBP (5/6/2025, 7:00:00 PM)
0.96
0 (0%)
The current stock price of HBP.CA is 0.96 CAD. In the past month the price increased by 9.09%. In the past year, price decreased by -8.57%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EDT.CA | SPECTRAL MEDICAL INC | N/A | 236.65M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 235.89M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 190.72M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 175.18M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 74.31M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 14.71 | 68.55M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 65.22M | ||
BLU.CA | BLUENERGIES LTD | N/A | 57.06M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 56.01M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 53.76M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 38 | 53.59M | ||
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 30.85M |
Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario and currently employs 7 full-time employees. The firm is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.
HELIX BIOPHARMA CORP
Bay Adelaide Centre - North Tower 40, Temperance Street, Suite 2700 Toronto
TORONTO ONTARIO L4B 3J9 CA
CEO: Heman Chao
Employees: 7
Phone: 16046842181
The current stock price of HBP.CA is 0.96 CAD.
The exchange symbol of HELIX BIOPHARMA CORP is HBP and it is listed on the Toronto Stock Exchange exchange.
HBP.CA stock is listed on the Toronto Stock Exchange exchange.
HELIX BIOPHARMA CORP (HBP.CA) has a market capitalization of 50.90M CAD. This makes HBP.CA a Micro Cap stock.
HELIX BIOPHARMA CORP (HBP.CA) currently has 7 employees.
HELIX BIOPHARMA CORP (HBP.CA) has a support level at 0.79 and a resistance level at 0.99. Check the full technical report for a detailed analysis of HBP.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HBP.CA does not pay a dividend.
HELIX BIOPHARMA CORP (HBP.CA) will report earnings on 2025-06-12.
HELIX BIOPHARMA CORP (HBP.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).
ChartMill assigns a technical rating of 4 / 10 to HBP.CA. When comparing the yearly performance of all stocks, HBP.CA turns out to be only a medium performer in the overall market: it outperformed 43.15% of all stocks.
Over the last trailing twelve months HBP.CA reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS decreased by -190.51% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -438% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to HBP.CA. The Buy consensus is the average rating of analysts ratings from 5 analysts.